Denshisha Co., Ltd. Introduces Urine Cancer Risk Test 'My Signal Scan' as Employee Benefit

Craif Inc. (headquarters: Shinjuku-ku, Tokyo; CEO: Ryuichi Onose; hereinafter Craif), which provides the urine cancer risk test 'My Signal', announced that Denshisha Co., Ltd. (headquarters: Kawagoe City, Saitama Prefecture; Representative Director: Ryuichi Hagiwara; hereinafter Denshisha) has introduced the urine cancer risk test 'My Signal Scan' as a welfare benefit.

Comment from Mr. Ryuichi Hagiwara, Representative Director of Denshisha Co., Ltd.

We believe that the most important thing for sustainable growth is 'human resources', and we are committed to creating a workplace where all employees can work with peace of mind for a long time.

This time, with the belief that it is important to support early detection of disease and improve health awareness not only for employees but also for their families who support them daily, we made the test available to all employees and their spouses. In addition, to make it easy to take this test, which can assess cancer risk without the hassle of going to a hospital or physical burden, we decided to cover the full cost. Many employees and their families empathized with this idea, and approximately 93% of eligible persons expressed their desire to take the test.

We will continue to aim to be a company that supports not only working people but also the peace of mind of their families.

About Denshisha Co., Ltd.

Founded in 1910 (Meiji 43). Centered in Saitama Prefecture, as a professional in electrical construction work, we aim to be a company that is loved by everyone through the fusion of 'advanced technology' that continues to progress in a wide variety of fields from public works to private companies and general home construction, and the 'traditional technology' built by our predecessors.

[Company Overview] Company name: Denshisha Co., Ltd.

Founded: January 1, 1910 Established: December 17, 1949 Head office: 14-4 Mikubo-cho, Kawagoe City, Saitama Prefecture Representative: Representative Director Ryuichi Hagiwara Number of employees: 91 (as of April 1, 2026) URL: https://www.denseisya.co.jp

About 'My Signal Scan'

'My Signal Scan' is a test that extracts microRNA from urine and analyzes it with AI to evaluate the risk of 10 types of cancer* including pancreatic cancer, from stage 1 by cancer type. It is a test that can be performed without burden on the body simply by collecting urine.

For details, please visit the website.

https://misignal.jp/

'My Signal Scan' is not a medical device. It determines risk by statistically calculating analyzed information, and is not a substitute for a medical 'diagnosis' of whether or not one has cancer. Even if the risk is judged to be low, it does not mean that there is no cancer or that one will not develop cancer in the future.

* Ovarian cancer and breast cancer are tested only for women, prostate cancer only for men.

About Craif

Craif is a bio-AI startup founded in 2018, dedicated to early cancer detection. By integrating its proprietary analysis technology platform 'NANO IP® (NANO Intelligence Platform)', which accurately detects various biomarkers such as DNA and microRNA from body fluids including urine, with AI technology, Craif develops innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely disseminating the power of biotechnology and AI to society, we promote our vision of 'Realizing a society where people can live out their natural lifespan'.

[Company Overview]

Company name: Craif Inc. (Japanese: クライフ, English: Craif Inc.)

Representative: Representative Director Ryuichi Onose

Established: May 2018

Capital: 100 million yen (as of April 1, 2025)

Business: Research and development of next-generation testing for early detection of diseases mainly in the cancer field and realization of personalized medicine; provision of urine cancer risk test 'My Signal®'

Head office: THE PORTAL iidabashi B1F, 8-30 Shingogocho, Shinjuku-ku, Tokyo

URL: https://craif.com/l